Publications on Special Topics About NCI-MATCH
|
|||
Journal | Topic | Title and Citation | Lead & Corresponding Authors |
Seminars in Oncology | Overview | Molecular Analysis for Therapy Choice: NCI MATCH Conley BA. Semin Oncol. 2014 Jun;41(3):297-9 |
Barbara A. Conley James H. Doroshow |
Chinese Clinical Oncology | Overview | An overview of the NCI Precision Medicine trials-NCI MATCH and MPACT Do K. Chin Clin Oncol. 2015 Sep;4(3):31 |
Khanh Do Alice P. Chen |
Journal of Molecular Diagnostics |
Next-Gen Sequencing Assay |
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial Molecular Analysis for Therapy Choice Clinical Trial Lih CJ. J Mol Diagn. 2017 Mar;19(2):313–327 |
Chih-Jian Lih P. Mickey Williams |
Current Problems in Cancer | Next-Gen Sequencing Assay | Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience Lih CJ. Curr Probl Cancer. 2017 May-Jun;41(3):201-211 |
Chih-Jian Lih Naoko Takebe |
Current Problems in Cancer | Defining Precision | Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH O’Sullivan Coyne G. Curr Probl Cancer. 2017 May-Jun;41(3):182-193 |
Geraldine O’Sullivan Coyne Alice P. Chen |
Clinical Cancer Research | Immunohisto-chemical Assays | Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial Koury JD. Clin Cancer Res. 2018 Feb 1;24(3):521–531 |
Joseph D. Khoury |
Journal of the National Cancer Institute |
Implementation | The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design Flaherty KT. J Natl Cancer Ins. 2020 Jan 10;pii:djz245 |
Keith T. Flaherty Peter J. O’Dwyer |
JCO Precision Oncology | Physician Survey | Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial Chen AP, JCO Precision Oncology no 4 (Oct 5, 2020) 1207-1216 |
Alice P. Chen |
Journal of Clinical Oncology | Central Screening Cohort | Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) Flaherty KT, J Clin Oncol. 2020 Oct 13: JCO.19.03010 |
Keith T. Flaherty |
Final Results for NCI-MATCH Treatment Arms
|
|||
Journal | Arm | Title and Citation | Lead Author |
Annals of Oncology | Q | Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Subprotocol Q Jhaveri KL. Ann Oncol. 2019 Nov 1;30(11):1821-1830 |
Komal L. Jhaveri |
Journal of Clinical Oncology | Z1D | Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study Azad NS. J Clin Oncol. 2019 Nov 25:JCO.1900818 |
Nilofer S. Azad |
Clinical Cancer Research | R | Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: Results from NCI-MATCH (EAY131) Johnson DB. Clin Cancer Res. 2020 Jan 10 |
Douglas B. Johnson |
Journal of Clinical Oncology | W | Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W Chae YK. J Clin Oncol. 2020 May 28:JCO.19.02630 |
Young K. Chae |
Journal of Clinical Oncology | H | Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H Salama AKS. J Clin Oncol. 2020 Aug 06:JCO.20.00762 |
April K.S. Salama |
JAMA Oncology | Y | Effect of Capivasertib in Patients with an AKT1 E17K-mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial Kalinsky KM. JAMA Oncol. 2020 Dec 30 |
Kevin M. Kalinsky |
Clinical Cancer Research | Z1A | Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors Cleary JM. Clin Cancer Res. 2021 Feb 26 |
James M. Cleary |
© 2012-2020 ECOG-ACRIN Cancer Research Group. All rights reserved. | Disclaimer